These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 31559849)

  • 1. Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia.
    Paul S; DiPippo AJ; Ravandi F; Kadia TM
    Future Oncol; 2019 Dec; 15(34):3885-3894. PubMed ID: 31559849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
    Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of quizartinib in the treatment of acute myeloid leukemia.
    Ostronoff F; Estey E
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study.
    Takahashi T; Usuki K; Matsue K; Ohno H; Sakura T; Imanaka R; Murakami M; Ohwada S; Takagi T; Sakajiri S
    Int J Hematol; 2019 Dec; 110(6):665-674. PubMed ID: 31473943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
    Cortes JE; Kantarjian H; Foran JM; Ghirdaladze D; Zodelava M; Borthakur G; Gammon G; Trone D; Armstrong RC; James J; Levis M
    J Clin Oncol; 2013 Oct; 31(29):3681-7. PubMed ID: 24002496
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Naqvi K; Ravandi F
    Leuk Lymphoma; 2019 Aug; 60(8):1866-1876. PubMed ID: 30997851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
    Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quizartinib (AC220): a promising option for acute myeloid leukemia.
    Zhou F; Ge Z; Chen B
    Drug Des Devel Ther; 2019; 13():1117-1125. PubMed ID: 31114157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
    Marensi V; Keeshan KR; MacEwan DJ
    Biochem Pharmacol; 2021 Jan; 183():114348. PubMed ID: 33242449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
    Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
    Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
    Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
    Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
    Sexauer A; Perl A; Yang X; Borowitz M; Gocke C; Rajkhowa T; Thiede C; Frattini M; Nybakken GE; Pratz K; Karp J; Smith BD; Levis M
    Blood; 2012 Nov; 120(20):4205-14. PubMed ID: 23012328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.
    Moore AS; Faisal A; Mak GWY; Miraki-Moud F; Bavetsias V; Valenti M; Box G; Hallsworth A; de Haven Brandon A; Xavier CPR; Stronge R; Pearson ADJ; Blagg J; Raynaud FI; Chopra R; Eccles SA; Taussig DC; Linardopoulos S
    Blood Adv; 2020 Apr; 4(7):1478-1491. PubMed ID: 32282883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
    Smith CC; Wang Q; Chin CS; Salerno S; Damon LE; Levis MJ; Perl AE; Travers KJ; Wang S; Hunt JP; Zarrinkar PP; Schadt EE; Kasarskis A; Kuriyan J; Shah NP
    Nature; 2012 Apr; 485(7397):260-3. PubMed ID: 22504184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B; Zhao Y; Wang X; Gong P; Ge W
    Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.